Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

kINPen

Financiado

Cerrado

Developing a high innovative portable cold plasma device for efficient healing o...

Developing a high innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new techno... ver más

30/04/2019

NEOPLAS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NEOPLAS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

NEOPLAS

50.00K€ | Lider

NOVALTI, S.A.

401.65K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-113987RB-I00 APOSITOS TOPICOS FABRICADOS MEDIANTE ELECTROHILADO O POR IMP... 155K€ Cerrado

PDC2021-121405-I00 ADAPTACION Y VALIDACION DEL PROCESO DE FABRICACION DE APOSIT... 144K€ Cerrado

PLASOMA Cold plasma cures chronic wounds a sparkling solution 4M€ Cerrado

WoundRinse Preventing Chronic wound infections with a novel antibiotic... 71K€ Cerrado

MIMESIS Development of biomaterials through mimesis of plant defensi... 2M€ Cerrado

STIMULUS Stimuli Responsive Materials for the Rapid Detection and Tre... 4M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2018-12-04
Fecha Fin: 2019-04-30

Líder del proyecto

NEOPLAS GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or LED, are less efficient, given their cost, unpleasant feeling, treatment-time or required area. Therefore, neoplas GmbH successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals. It stimulates and accelerates physiological wound healing and is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country. The production costs have been calculated with 5.900 €/ unit in the first 3 years and with a rising production the costs will be reduced to ca. 4.600 €/unit. The sales price is targeted with 8.900 €/unit and will allow a calculated return on investment in under 18 months.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores